Scientists confirm safety of MitoQ and kidney health

This study adds to a growing body of evidence supporting the safety profile of MitoQ® Mitoquinol (MitoQ) and its potential role in promoting kidney health. 

The kidneys are among the most metabolically active organs in the body, and they’re highly dependent on optimal mitochondrial function to their many important functions. When it comes to supplements, any compound that is engineered to accumulate within the mitochondrial matrix must be carefully evaluation for renal safety, particularly at higher doses.  

The study

Researchers from the University of Auburn, Alabama carried out a randomized, cross-over, placebo-controlled baseline-comparison trial in 15 healthy adults to study the safety of MitoQ at high doses and kidney health. Participants were randomly assigned either a placebo or MitoQ at a dose of 100-160mg (according to bodyweight) and blood samples were taken prior to taking MitoQ capsules, then urine was collected 4-5 hours afterwards. After a 72 hour wash-out period the dosing was reversed and those on placebo were given MitoQ, and those randomly assigned MitoQ took the placebo.

It is worth noting that the recommended consumer dose of MitoQ is currently 10-20mg per day, and MitoQ’s safety has previously been proven at doses of up to 80mg.

The levels of creatinine (a waste product) in the participants’ blood and urine were assessed to determine how well their kidneys were working as the body’s filtration system. Creatinine should not be confused with creatine, an amino acid involved in energy supply. Creatinine levels outside of a healthy range can indicate kidney problems. To complete a holistic assessment of kidney health, the participants’ urine was also tested for a range of other biological markers (biomarkers) relating to kidney injury.